CD4 and graft versus host disease: These findings provide further support for reduced alloreactive CD4+ conventional T-cell proliferation at day +7 and preferential Treg recovery at day +21 as potential biomarkers for effective GVHD control by PTCy as identified in our previous publications on optimal dosing and timing of PTCy (5, 6).